What topics does this cannabis study cover?

This study covers research on: THC, Anxiety, Sleep, Nausea, Mental Health.

Where was this research published?

Published in Drug and alcohol dependence on May 26, 2026.

Dispensary advice may not be as safe as the products sold

Q: What did this research study find?

Researchers assessed **130 cannabis retailers** in **five U.S. cities** and found that shoppers were asked for identification at **87.7%** of locations.

Mystery shopper assessments of cannabis retailer practices and regulatory compliance in five U.S. states, 2025.

Drug and alcohol dependence • May 26, 2026 • Highly Relevant

🤖

AI Summary

This mystery shopper study assessed 130 cannabis retailers across five U.S. cities and states in summer 2025. Researchers examined age verification and how staff discussed cannabis use for anxiety, insomnia, pregnancy-related nausea, driving, interstate transport, and other intoxicating products. Shoppers were asked for identification at 87.7% of retailers, indicating that age checks were common but not universal.

The findings also raised concerns about the quality and safety of retail guidance. More than 88% of staff said cannabis helps with anxiety and insomnia, while responses about pregnancy-related nausea and driving varied considerably. Staff sometimes provided advice on concealing cannabis during interstate travel or minimized the risk of being caught. The researchers concluded that retailers frequently made prohibited health claims and downplayed risks, highlighting the need for continued surveillance, stronger oversight, and better enforcement. For consumers, the results suggest that dispensary advice should not be treated as a substitute for guidance from qualified health professionals.

💡 Key Findings

Researchers assessed 130 cannabis retailers in five U.S. cities and found that shoppers were asked for identification at 87.7% of locations.

High

80%

More than 88% of retail staff said cannabis helps with anxiety and insomnia, reflecting frequent health-related claims in retail settings.

High

80%

Advice about pregnancy-related nausea and driving was inconsistent: 40.8% warned against cannabis use during pregnancy, while 36.2% suggested it could help; 58.5% warned against driving after use, but 50.0% said the risk depended on the individual or situation.

High

80%

The study found that some staff offered ways to make interstate cannabis transport harder to detect, while others minimized the likelihood of being caught, raising concerns about regulatory compliance and public safety.

Good

75%

The researchers concluded that cannabis retailers frequently made prohibited health claims and minimized risks, supporting the need for stronger regulatory oversight and enforcement.

High

85%

📄 Original Abstract

This study used mystery shoppers to assess cannabis retail practices in 5 US states regulating legal nonmedical cannabis retail. This mystery shopper study assessed 130 cannabis retailers in 5 cities (Los Angeles [LA], California; Las Vegas [LV], Nevada; Denver, Colorado; Portland, Oregon; Seattle, Washington) in summer 2025. Researchers recorded: 1) age verification; and 2) retail staff responses to inquiries about: a) use for anxiety, sleep, pregnancy-related nausea, etc.; b) use-related risks/cautions; c) interstate cannabis transport; and d) availability of derived intoxicating cannabis products (DICPs) and 'mushrooms' (psilocybin). Mystery shoppers were asked for ID at 87.7% of retailers. When asked, most (>88%) retail staff responded that cannabis helps with anxiety and insomnia. While 40.8% warned against use for pregnancy-related nausea, 36.2% suggested it helps and 24.6% said it depends on the person/situation. Over half (58.5%) warned against driving post-use, but 50.0% said it depends (on person/situation). When asked about interstate transport, several indicated not to (42.3%) and/or it was illegal (39.2%); however, 44.6% indicated ways to pack cannabis to be undetectable, and 27.7% said not to worry about getting caught. Retail staff generally indicated DICPs are not as safe as delta-9 THC (27.7%) or are illegal (20.0%). The majority said mushrooms were illegal (67.7%), but 53.8% indicated they were easy to obtain, and 29.2% suggested their mental health benefits. Cannabis retailer frequently made prohibited health claims and minimized risks, reinforcing public health concerns and the need for ongoing cannabis retail surveillance and stronger regulatory oversight and enforcement.

Paper Type

📄 Research

Publication

Journal: Drug and alcohol dependence
Published: May 26, 2026
PMID: 42224931
DOI: 10.1016/j.drugalcdep.2026.113218

Authors (11)

Carla J Berg Department of Prevention and Community Health, Milken Institute School of Public Health, George Washington University, Washington, DC, USA; George Washington Cancer Center, George Washington University, Washington, DC, USA. Electronic address: carlaberg@gwu.edu.
Cassidy R LoParco Department of Prevention and Community Health, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
Matthew E Rossheim Department of Health Administration and Health Policy, College of Public Health, The University of North Texas Health Science Center, Fort Worth, TX, USA.
Darcey M McCready Department of Prevention and Community Health, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
Lauren Langan Center for Public Health Law Research, Beasley School of Law, Temple University, Philadelphia, PA, USA.
+6 more authors